A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy
Introduction: Pituitary metastases (PM) are rare events and to date only very few cases of melanoma PM have been described in literature up to now.Case Presentation: We describe the clinical history of a 33-year-old male patient who underwent surgical excision of an inter-scapular melanoma in 2008....
Main Authors: | Marilda Mormando, Giulia Puliani, Agnese Barnabei, Rosa Lauretta, Marta Bianchini, Alfonsina Chiefari, Michelangelo Russillo, Francesco Cognetti, Luisa Romano, Marialuisa Appetecchia |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2020.00471/full |
Similar Items
-
Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements
by: Alia Thawer, et al.
Published: (2021-09-01) -
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01) -
Dabrafenib plus trametinib versus nivolumab for advanced melanoma
by: Daniela Lahoz, et al.
Published: (2023-02-01) -
Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
by: Sandip Ganguly, et al.
Published: (2021-09-01) -
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
by: Nora Isberner, et al.
Published: (2022-09-01)